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Abstract
Background: The differential diagnosis of thrombotic microangiopathy (TMA) is complex however the rapid
diagnosis of the underlying condition is vital to inform urgent treatment decisions. A survey was devised with the
objective of understanding current practices across Europe and the Middle East, and of challenges when
diagnosing the cause of TMA.
Methods: Over 450 clinicians, from 16 countries were invited to complete an online survey.
Results: Of 254 respondents, the majority were nephrologists, had >10 years’ experience in their specialty, and had
diagnosed a patient with TMA. The triad of thrombocytopenia, haemolytic anaemia and acute kidney injury are the
main diagnostic criteria used. Responses indicate that a differential diagnosis of TMA is usually made within 1–2
(53%) or 3–4 days (26%) of presentation. Similarly, therapy is usually initiated within the first 4 days (74%), however
13% report treatment initiation >1-week post-presentation. Extrarenal symptoms and a panoply of other conditions
are considered when assessing the differential diagnosis of TMA. While 70 and 78% of respondents stated they
always request complement protein levels and ADAMTS13 activity, respectively. Diagnostic considerations of
paediatric and adult nephrologists varied. A greater proportion of paediatric than adult nephrologists consider
extrarenal manifestations clinically related to a diagnosis of TMA; pulmonary (45% vs. 18%), gastrointestinal (67% vs.
50%), CNS (96% vs. 84%) and cardiovascular (54% vs. 42%), respectively. Variability in the availability of guidelines
and extent of family history taken was also evident.
Conclusions: This survey reveals the variability of current practices and the need for increased urgency among
physicians in the differential diagnosis of TMA, despite their experience. Above all, the survey highlights the need
for international clinical guidelines to provide systematically developed recommendations for understanding the
relevance of complement protein levels, complement abnormalities and ADAMTS13 testing, in making a differential
diagnosis of TMA. Such clinical guidelines would enable physicians to make a more rapid and informed diagnosis
of TMA, therefore initiate effective treatment earlier, with a consequent improvement in patient outcomes.
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Background
Thrombotic microangiopathy (TMA) manifests as a
histological lesion of the microvasculature characterised
by thickened and swollen vessel walls, detachment of
endothelial cells, build-up of proteins and cell lysis ma-
terial in the sub-endothelial space, and obstruction of
the vascular lumen by platelet thrombi [1].
Thrombotic thrombocytopenic purpura (TTP) and
haemolytic uraemic syndrome (HUS) are the two most
common clinical conditions characterised by TMA le-
sions but have differing aetiology, pathophysiology and
management strategies [1]. TTP is a systemic disorder of
microvascular thromboses due to a deficiency in a disin-
tegrin and metalloproteinase with a thrombospondin
type 1 motif, member 13 (ADAMTS13) activity, as a re-
sult of autoantibodies or genetic mutations. A severe re-
duction of ADAMTS13 activity (<10%) results in the
formation of ultra-high molecular weight von Willeb-
rand factor multimers, causing aggregation of platelets
and end-organ ischaemia [2]. HUS meanwhile, is a clin-
ical syndrome characterised by the obstruction of micro-
vasculature (most commonly in the kidney) by platelet-
fibrin thrombi despite normal ADAMTS13 activity.
Shiga-toxin producing Escherichia coli (STEC) is the
most common cause of HUS (STEC-HUS) [3]. History
of an accompanying condition, including the presence of
non-STEC infections such as Streptococcus pneumoniae
or influenza virus infection, malignant hypertension,
transplantation, pregnancy and child birth, or drug usage
may suggest a diagnosis of secondary TMA [3]. The
atypical form of HUS (aHUS) is a rare, life-threatening
disease of chronic, uncontrolled complement activation
that leads to TMA with severe organ damage. The dif-
ferential diagnosis of aHUS requires the exclusion of
TTP and STEC-HUS [1]. The rapid progression of
TMA, associated with potentially irreversible damage to
organs in patients with aHUS, indicates a need for ur-
gent treatment. Historically, disease outcomes have been
poor, despite previous practice to manage aHUS by in-
tensive plasma exchanges [4]. More recently, eculizu-
mab, a humanised monoclonal antibody that binds to
the complement protein C5 preventing the formation of
the membrane attack complex, has been shown to be ef-
fective in treating patients with aHUS [5–7]. A recent
report demonstrated a greater and more sustained re-
covery in renal function when eculizumab therapy is ini-
tiated within 7 days of aHUS onset [8].
The differential diagnosis of TMA is complex but im-
portant to inform treatment decisions. Consensus guide-
lines for the differential diagnosis of TMA were updated
in 2015 [1], however real-world evidence on the current
diagnosis and treatment practices has not been reported.
We hypothesised that there are areas of uncertainty in
the work-up of patients with TMA, leading to potential
delays in establishing the final diagnosis, putting pa-
tient’s lives at a higher risk.
We devised a survey with the objective of understand-
ing current practices in the diagnosis of TMA and aHUS
across Europe and the Middle East and challenges when
diagnosing the cause of TMA.
Methods
Survey
The survey was developed by the authors in 2015. Initial
questions were proposed in a draft version which was dis-
cussed by all the authors. The draft was subsequently re-
vised, including the removal and addition of questions and
possible responses. The final version of the survey was dis-
tributed to the authors for review as an additional quality
control measure and was distributed between January and
March 2016, using the online tool surveymonkey.com. The
authors distributed the survey to paediatric and adult neph-
rology centres, multi-disciplinary hospitals, and academic
clinics within their countries or regions. The survey was
composed of 36 questions with multiple choice answers
provided (Additional file 1: Table S1). Questions included
characteristics of the respondent’s place of work, and their
experience in the diagnosis and management of patients
with TMA and aHUS. No personal information was col-
lected or stored. The survey used adaptive questioning (cer-
tain questions were only displayed based on previous
responses) to avoid redundant questions. Respondents
could review and change their answers, through a “Back”
button function. The survey was translated into Russian
and German for non-English speaking participants in those
regions. Participants were informed that data collected
would be published in a research article.
Participants
An email invitation with a link to the survey was sent to
over 450 clinicians, from 16 countries, Belgium, Czech
Republic, Denmark, Finland, France, Germany, Italy,
Netherlands, Norway, Russia, Saudi Arabia, Spain,
Sweden, Switzerland, Turkey and UK.
Data analysis
The responses were compiled in a spreadsheet and de-
scriptive analyses were performed. Participant and centre
name were not requested in the survey. Not all respon-
dents answered the survey in its entirety, therefore the
number of responses per individual question are stated.
Results are reported as counts and percentages of re-
sponses received.
Results
Participation
Two hundred and fifty-four clinicians from 16 countries
participated: Belgium (2), Czech Republic (2), Denmark
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(2), Finland (17), France (24), Germany (14), Italy (21),
Netherlands (47), Norway (4), Russia (42), Saudi Arabia
(1), Spain (29), Sweden (3), Switzerland (1), Turkey (37)
and UK (8). Eighty-three percent of the 254 respondents
completed the survey in its entirety. Of the 254 respon-
dents, 82% were nephrologists, 69% had more than
10 years’ experience in their specialty, and 89% had diag-
nosed a patient with TMA. Table 1 describes the charac-
teristics of clinicians that participated in the survey.
Additional professionals responding included haematol-
ogists, paediatricians and intensive care unit specialists.
Diagnosis of TMA
Results show that a differential diagnosis of TMA is usu-
ally made within 1–2 (53%) or 3–4 days (26%) of
presentation. Similarly, therapy is usually initiated within
1–2 (44%) or 3–4 days (30%), however 13% reported
treatment initiation >1-week post-presentation (Fig. 1).
Respondents indicated that thrombocytopenia, haemo-
lytic anaemia and acute kidney injury (AKI) are the main
clinical diagnostic criteria used (Fig. 2). In working-up a
TMA diagnosis 70 and 78% of respondents stated they
always request complement protein levels and
ADAMTS13 activity, respectively. However, only 66%
agreed that an ADAMTS13 activity >10% rules out TTP.
Neurological, gastrointestinal, cardiovascular and pul-
monary symptoms and a variety of other conditions are
considered when assessing the differential diagnosis
(Fig. 2). Twenty-two percent of respondents reported
that they complete a full family tree when they diag-
nose a patient with TMA. Over 65% of respondents
indicated that renal biopsies are only requested when
a diagnosis is not clear.
Diagnosis of aHUS
For the diagnosis of aHUS, 93% of respondents request
ADAMTS13 activity tests and 83% request complement
protein levels (Fig. 3). Fifty-four percent of responding
clinicians stated that guidelines for the diagnosis of
TMA are available within their hospital (Table 1).
These guidelines were similarly described as being local
to their institute, national or international. Approxi-
mately half of the respondents routinely perform gen-
etic testing, and this is paid for by the hospital in 46%
of cases.
Paediatric and adult nephrologist diagnostic practices
A sub-analysis compared the current diagnostic
practices of paediatric (n = 75) and adult nephrolo-
gists (n = 132; Table 2). A greater proportion of
paediatric than adult nephrologists considered pul-
monary, gastrointestinal, central nervous system
(CNS) and cardiovascular manifestations clinically
related to a diagnosis of TMA. As would be
Table 1 Respondent characteristics
Question and response options n (%)
Institute type:
Academic centre 216 (85)
Private hospital 35 (14)
Private practice 6 (2)
Department/division type:
Nephrology 133 (52)
Paediatric nephrology 68 (27)
Intensive care 6 (2)
Emergency ward 0 (0)
What is your current speciality?
Adult nephrologist 132 (52)
Paediatric nephrologist 75 (30)
ICU specialist 6 (2)
How many years have you been practicing your current speciality?
< 1 year 4 (2)
1–5 years 29 (11)
6–10 years 47 (18)
> 10 years 175 (69)
Have you ever personally diagnosed a patient with TMA (or validated
the diagnosis of TMA in a patient referred to you)?a
Yes 221 (89)
No 28 (11)
Are there any guidelines in place for the diagnosis of TMA at
your hospital?b
Yes 121 (54)
No 105 (46)
Are the guidelines local to your institute, national or international?c
Local 41 (34)
National 47 (39)
International 34 (28)
Percentages are based on 254 responses, with the exception of a(n = 248),
b(n = 226) and c(n = 122)
0 20 40 60 80 100
Percentage of responses
TMA diagnosis
(n=227)
Treatment initiation
(n=227)
53
44
1326
30
7
1314
1-2 days 3-4 days 5-7 days >1 week
Fig. 1 Time taken to make a differential diagnosis of TMA and
initiate therapy. The aim was to determine the time taken to take
specific action following differential diagnosis and not to define the
treatments provided
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expected when assessing the differential diagnosis,
paediatric nephrologists more often considered infec-
tions and cobalamin metabolism disorders than adult
nephrologists, and less often considered scleroderma,
malignancy and HELLP (haemolysis, elevated liver
enzyme levels, and low platelet levels) syndrome.
Paediatric nephrologists also requested tests for
enterohaemorrhagic Escherichia coli (EHEC) infec-
tion more frequently than adult nephrologists.
Paediatric nephrologists are more likely to
complete a full family tree when investigating the
patients’ family history compared with adult nephrol-
ogists (41% vs 16%). Paediatric nephrologists are also
more likely to routinely request genetic testing than
adult nephrologists (69% vs 41%). Guidelines for the
diagnosis of TMA are more readily available to
paediatric nephrologists (72%) than adult nephrolo-
gists (42%).
The most challenging aspect of an aHUS diagnosis
for paediatric nephrologists is the delay in getting
some laboratory results. However, the absence of a
single reliable diagnostic test and the heterogeneity
of disease presentation are the most challenging
aspects of diagnosing aHUS for adult nephrologists
(Table 2).
Discussion
This survey provides a large source of information de-
scribing current practices in the differential diagnosis of
TMA amongst experienced clinicians in 16 countries in
Europe and the Middle East.
90
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Clinical signs and laboratory results
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Clinical conditions
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Haemolytic anaemia
Acute renal failure
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Increased LDH
Central nervous system
Gastrointestinal
Cardiovascular
Pulmonary
Systemic lupus erythematosus
Autoimmune haemolytic anaemia (AIHA)
Antiphospholipid antibody syndrome
Drug induced (e.g. chemotherapy)
Infections (e.g. Streptococcus pneumoniae)
Sepsis
Pregnancy (HELLP syndrome)
Malignancy
Fig. 2 The main clinical signs and laboratory results (n = 229), extrarenal organ systems (n = 229) and clinical conditions (n = 227) considered
when assessing the differential diagnosis of TMA
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Fig. 3 Tests requested to work up the diagnosis of aHUS (n = 221)
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Clinical guidelines are an important tool to facilitate clin-
ical decision making and promote the delivery of evidence-
based best practice [9]. However, clinical guidelines for rare
diseases are often difficult to formulate due to a lack of
quality evidence, surveys of clinical practices, and data
about patients’ opinion (https://www.iqwig.de/download/
V10-01_Executive_Summary_Evidence_for_guidelines_on_-
rare_diseases.pdf). Recommendations provided within
current guidelines are opinions, based on the best available
scientific evidence [1, 10–12].
Table 2 Comparison of paediatric and adult nephrologist’s diagnostic practices for TMA
Response n (%)a
Paediatric nephrologist
n = 75
Adult nephrologist
n = 132
Apart from renal symptoms, which other organ manifestations would you consider clinically related to a diagnosis of TMA?
Central nervous system 64 (96) 103 (84)
Gastrointestinal 45 (67) 62 (50)
Cardiovascular 36 (54) 52 (42)
Pulmonary 30 (45) 22 (18)
What other conditions do you usually consider when assessing the differential diagnosis of TMA?
Antiphospholipid syndrome 41 (60) 96 (79)
Autoimmune haemolytic anaemia 42 (62) 96 (78)
Clotting disorder 45 (66) 25 (21)
Cobalamin metabolism disorder 18 (26) 43 (35)
Drug induced 44 (65) 87 (71)
HIV 15 (22) 38 (31)
Infections 55 (81) 58 (48)
Malignancy 22 (32) 78 (64)
Pregnancy (HELLP syndrome) 15 (22) 86 (71)
Scleroderma 9 (13) 48 (39)
Sepsis 36 (53) 71 (58)
Systemic lupus erythematosus 49 (72) 103 (84)
Otherb 4 (7) 11 (9)
How extensive is your investigation of the patients’ family history?
Ask the patient 21 (31) 75 (61)
Investigate immediate family 19 (28) 28 (23)
Complete a full family tree 28 (41) 19 (16)
Do you routinely perform genetic testing?
Yes 46 (69) 49 (41)
No 21 (31) 70 (59)
Are there any guidelines in place for the diagnosis of TMA at your hospital?
Yes 49 (72) 51 (42)
No 19 (28) 70 (58)
When the differential diagnosis of TMA was aHUS, what was the most challenging aspect of the diagnosis?c
Absence of guidelines 2.1 2.5
Delay in getting some laboratory results 3.7 3.4
Absence of a single and reliable diagnostic test 3.6 3.5
Heterogeneity of disease presentation 2.9 3.5
aPercentage obtained from the number of responses received for individual questions
bFifteen respondents also selected “other” considerations as free text; these included malignant hypertension (n = 6), viral infections (n = 3; H1N1, hantavirus and
parvovirus), disseminated intravascular coagulation (n = 2), transplantation (n = 2), vasculitis (n = 2), aHUS (n = 1), HUS (n = 1), pre-eclampsia (n = 1), TTP (n = 1), and
AKI of unknown aetiology (n = 1). Clinicians could include >1 answer in response to ‘Other’
cClinicians were asked to grade their response from 1 (least challenging) to 5 (most challenging), data are presented as mean score. HELLP, haemolysis, elevated
liver enzyme levels, and low platelet levels; HIV, human immune deficiency virus; TMA, thrombotic microangiopathy
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Responses suggest the awareness, use, or perceived im-
portance of published recommendations [1, 10–12]
available for the management of patients with TMA
is inconsistent between countries and even within
hospitals from the same country. Adult nephrologists
seem to be less aware of published guidelines,
however this was rated as the least challenging as-
pect of making an aHUS diagnosis suggesting limited
clinical impact.
In accordance with recent recommendations [1, 10–12]
the triad of haemolytic anaemia, thrombocytopenia and
AKI were the three main criteria indicating a diagnosis of
TMA. However, the presence of schistocytes and in-
creased lactate dehydrogenase (LDH) were not considered
primary criteria in the diagnosis of TMA by many physi-
cians. Considering the rapid progression and severity of
TMA, guidelines recommend a rapid differential diagnosis
to be established allowing for appropriate supportive mea-
sures to be taken with the first 48 h from admission [1]. In
practice however, approximately half of clinicians state a
diagnosis of TMA takes more than 3 days. Similarly,
therapeutic strategies are initiated after 3 days or more in
the majority of cases (57%). These data support those
from a recent survey conducted by the aHUS Alliance
whereby less than 55% of 233 patients with aHUS received
their diagnosis within a week of presentation [13]. Deter-
mining ADAMTS13 activity levels and the absence of
STEC infection in a timely manner (<24 h) is crucial in
discriminating TTP from other TMA [1, 2]. By identifying
ADAMTS13 activity levels early, appropriate treatment
can be initiated quickly, and patients without TTP avoid
unnecessary plasma exchange. Thereby patient outcomes
may be improved.
Despite being part of recommended algorithms for the
differential diagnosis of TMA [1, 10] only two-thirds of
respondents agreed that an ADAMTS13 activity >10%
rules out TTP. aHUS is a rare disease and as such
awareness of the role of ADAMTS13 testing in the dif-
ferential diagnosis may be low. One guideline recom-
mends ADAMTS-13 activity <5–10% is indicative of
TTP [1]. However, other reports have used <5% [11] and
<10% [14] as a reference value to inform on diagnosis. It
is possible that some centres may adopt ADAMTS-13
activity >5% as a lower limit to rule out a differential
diagnosis of TTP, which may partially explain this result.
Alternatively, there are also reports stating 10–25% of
TTP patients have normal ADAMTS-13 activity [15]
with activity levels varying from 33 to 100% among pa-
tients with apparent idiopathic TTP [16]. The response
received in the survey may reflect that some physicians
are not medically convinced that ADAMTS13 > 10%
rules out TTP in 100% of cases.
The systemic nature of TMA leads to the involvement
of the microvasculature of organs other than the kidney,
with neurological manifestations being the most com-
mon [17]. This is reflected in 87% of respondents stating
they consider neurological symptoms when considering
a TMA diagnosis. However, it is important to consider
that many other organs can be affected by TMA [18].
One guideline recommends a complete and detailed
clinical history should be made for all TMA patients,
including personal and family history [1], unless an EHEC
infection is obvious. Current data suggest this is not rou-
tinely the case, as half of respondents reported that a fam-
ily history would be determined by asking the patient
only. A more thorough family history would be beneficial,
as the majority of the reported aHUS associated mutations
are dominant but with incomplete penetrance [17].
Gene mutations or polymorphisms affecting com-
plement regulators or proteins are identified in 60–
70% of aHUS patients [19, 20]. While identification of
a complement mutation or anti-complement factor H
(CFH) inhibitory antibody is not required to make a
diagnosis of aHUS or initiate therapy, it does inform
on prognosis and risk of recurrence [1, 8, 20, 21]. In
this study, genetic testing is routinely performed by
just under half of the clinicians managing patients
with aHUS, but more commonly by paediatric ne-
phrologists. In contrast, a survey conducted by the
aHUS Alliance observed 84% of patients with aHUS
have had or are awaiting to undergo genetic testing
[13]. In our survey the percentage was clearly lower,
in addition, a family tree was completed for only 41%
of paediatric patients and 16% of adult patients. Our
survey does not allow understanding of the reasons
for this relatively low proportion for genetic testing.
The lack of guidelines, the cost, the time taken to get
results, as well as difficulty in interpreting the results,
may influence the extent to which a family history is
investigated. The introduction of uniform reporting,
tailored to non-geneticists may increase confidence in
physicians requesting genetic tests. This may in turn
result in a more consistent application of genetics to
inform on prognosis and the risk of recurrence, and
provide information to expand our understanding on
the natural course of aHUS.
There are limitations to interpreting data collected by
surveys. Here, the survey was sent to email addresses
available to the authors and may have led to some sur-
vey bias. Additionally, not all countries were equally rep-
resented, however despite this the survey covered a large
and unprecedented amount of countries. Secondly, we
cannot be sure of the precise number of recipients, as
clinicians may have forwarded the survey to colleagues.
However, we estimate a satisfactory response rate com-
pared with the average for web-based surveys [22]. Based
on a meta-analysis of 68 web-based surveys in 49 studies
[23], we estimate 641 clinicians would have been invited
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for our response rate to be similar to the 39.6% reported
[23]. Thirdly, the majority of responses were provided by
experienced nephrologists and not physicians from other
specialties. As such, our results may not be applicable to
diagnostic practices of non-nephrology departments,
where awareness of this ultra-rare disease is likely to be
lower. Finally, the survey did not undergo a formal valid-
ation process; however, three drafts were subsequently
developed and reviewed by the authors prior to circulat-
ing the final survey to a large audience.
We hypothesised that there were areas of uncertainty in
the work-up of patients with TMA, leading to potential
delays in establishing the final diagnosis, putting patient’s
lives at a higher risk. This survey addressed many ele-
ments of the hypothesis however other aspects warrant
further investigation. The current survey focused on the
diagnosis, not on the management, of TMA. Real-world
information on the management practices of clinicians
treating patients with TMA would be of interest and a
worthwhile topic for a follow-up survey in the future.
Conclusion
This survey evaluated current clinical practices of experi-
enced paediatric and adult nephrologists in the diagnosis
of TMA including aHUS. We describe the variable prac-
tices in the differential diagnosis of TMA amongst respon-
dents, despite their considerable clinical experience. Our
survey suggests that some countries lack national guide-
lines and these should be put in place where possible.
Guidelines would serve to raise awareness of the availabil-
ity and relevance of ADAMTS13 and STEC testing to dis-
criminate TTP and STEC-HUS from aHUS. These clinical
guidelines could potentially increase awareness of the evi-
dence for genetic testing after the initial therapy has been
started and the importance of conducting a full family his-
tory, when presented with a genetic disease as a possible
diagnosis. Our results also suggest that having guidelines
does not guarantee their implementation; future activities
should focus more on the dissemination of knowledge and
education, to encourage guideline implementation. Con-
tinuing medical education courses on diagnostic and treat-
ment practices for TMA may be of benefit to clinicians.
Finally, there is the need for clear and practical guidelines
for general practitioners and primary care doctors, in
order to accelerate the diagnostic process. Systematically
developed guidelines will aid clinicians in diagnosing and
managing TMA, enabling a more rapid and informed
diagnosis and initiation of effective treatment earlier, with
a consequent improvement in patient outcomes.
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